Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cleo DiagnosticsASX:COV -2.82%10 EV-to-FCF is -15.57 as of Jul. 21, 2026. GuruFocus rates ASX:COV with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 414 Medical Devices & Instruments companies, Cleo Diagnostics ranks worse than 241545.65% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cleo Diagnostics's Enterprise Value is A$39.25 Mil.
Cleo Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.52 Mil. Therefore, Cleo Diagnostics's EV-to-FCF for today is -15.57.
The historical rank and industry rank for Cleo Diagnostics's EV-to-FCF or its related term are showing as below:
ASX:COV'
s EV-to-FCF Range Over the Past 10 Years
Min: -15.84 Med: 0 Max: 0
Current: -15.84
ASX:COV's EV-to-FCF is ranked worse than 100% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.21
vs ASX:COV: -15.84
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cleo Diagnostics's PE Ratio (TTM) for today is calculated as:
Cleo Diagnostics's share price for today is A$0.345.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cleo Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.029.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cleo Diagnostics EV-to-FCF Related Terms
Cleo Diagnostics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cleo Diagnostics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cleo Diagnostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleo Diagnostics EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cleo Diagnostics's EV-to-FCF falls into.
Cleo Diagnostics's current Enterprise Value is A$39.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cleo Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cleo Diagnostics (ASX:COV) has a EV-to-FCF of -15.57 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cleo Diagnostics and its competitors. According to the industry distribution chart, Cleo Diagnostics ranks #999999 out of 414 companies in the Medical Devices & Instruments industry.
Is Cleo Diagnostics' EV-to-FCF too high?
Cleo Diagnostics' current EV-to-FCF is -15.57. Based on the distribution chart, Cleo Diagnostics ranks #999999 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cleo Diagnostics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cleo Diagnostics ranks #999999 out of 414 companies for EV-to-FCF. This places Cleo Diagnostics in the lower half of its industry. The industry median EV-to-FCF is 23.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.21, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cleo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleo Diagnostics's current EV-to-FCF is -15.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current EV-to-FCF of -15.57. The current EV-to-FCF is -15.57. Cleo Diagnostics' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current EV-to-FCF is -15.57 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
10GF Score
Get the complete analysis for ASX:COV
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:COV has been successfully added to your 
